| Name | Title | Contact Details |
|---|
Emergency Care Programs is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clear skin can be life-changing, but it`s not easy to see a dermatologist. At Curology, we provide prescription medications custom-formulated for each patient`s skin and shipped directly to their door. We tailor the entire Curology experience specifically for patients with acne and anti-aging concerns, allowing us to provide incredibly personalized, effective and affordable care at scale. We`ve assembled a committed team of dermatology providers and created a secure online platform, bringing professional acne care and prescription treatment to tens of thousands of people who wouldn`t otherwise be able to access or afford it. Curology helps people see tremendous, long-term improvements previously accessible only to a small percentage of the population. Our formulas are already on tens of thousands of sinks across the US. Our technology enables 1:1 chats with real dermatology providers and lets users to share their journeys with an engaged and growing community. Members can upload photos and track their progress over SMS, as well as browse and post digital postcards to share victories and encourage others. Curology is headquartered in the beautiful Hayes Valley neighborhood of San Francisco.
Florida Blue is a subsidiary of a not-for-profit health solutions company dedicated to serving all Floridians in the pursuit of health. Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association, serving residents and businesses in the state of Florida.
Johnston Health is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Smithfield, NC. To find more information about Johnston Health, please visit www.johnstonhealth.org
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.